schliessen

Filtern

 

Bibliotheken

Renal effects of canagliflozin in type 2 diabetes mellitus

Background: Chronic kidney disease is commonly associated with type 2 diabetes mellitus (T2DM) and may impact the efficacy and safety of glucose-lowering therapies. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces blood glucose levels in patients with T2DM by lowering the renal th... Full description

Journal Title: Current medical research and opinion 2015-12-02, Vol.31 (12), p.2219-2231
Main Author: Perkovic, Vlado
Other Authors: Jardine, Meg , Vijapurkar, Ujjwala , Meininger, Gary
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Taylor & Francis
ID: ISSN: 0300-7995
Link: https://www.ncbi.nlm.nih.gov/pubmed/26494163
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_informaworld_taylorfrancis_310_1185_03007995_2015_1092128
title: Renal effects of canagliflozin in type 2 diabetes mellitus
format: Article
creator:
  • Perkovic, Vlado
  • Jardine, Meg
  • Vijapurkar, Ujjwala
  • Meininger, Gary
subjects:
  • Canagliflozin
  • Canagliflozin - adverse effects
  • Canagliflozin - therapeutic use
  • Chronic kidney disease
  • Diabetes Mellitus, Type 2 - drug therapy
  • Dose-Response Relationship, Drug
  • Humans
  • Hypoglycemic Agents - adverse effects
  • Hypoglycemic Agents - therapeutic use
  • Kidney
  • Kidney - drug effects
  • Kidney Function Tests
  • Renal Insufficiency - physiopathology
  • Renal Insufficiency, Chronic - physiopathology
  • Safety
  • Sodium-Glucose Transporter 2 - antagonists & inhibitors
  • Type 2 diabetes mellitus
ispartof: Current medical research and opinion, 2015-12-02, Vol.31 (12), p.2219-2231
description: Background: Chronic kidney disease is commonly associated with type 2 diabetes mellitus (T2DM) and may impact the efficacy and safety of glucose-lowering therapies. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces blood glucose levels in patients with T2DM by lowering the renal threshold for glucose, thereby promoting urinary glucose excretion. This review describes the pharmacology, efficacy and safety of canagliflozin according to kidney function in participants with T2DM. Methods: Published articles that reported efficacy, safety and pharmacokinetics/pharmacodynamics data for canagliflozin in patients with T2DM and impaired renal function, and renal safety data with canagliflozin in various populations of patients with T2DM through May 2015 were included. Results: Early transient reductions in estimated glomerular filtration rate were observed with canagliflozin; these changes generally stabilized or attenuated over time and reversed after discontinuation, suggesting no renal (glomerular or tubular) damage with canagliflozin treatment. Urinary albumin-to-creatinine ratios were reduced with canagliflozin. Canagliflozin was generally well tolerated in patients with normal or mild to moderately impaired renal function, with a modestly higher incidence of renal-related adverse events and volume depletion-related adverse events in patients with moderate renal impairment. Adverse events related to potassium elevations were infrequent with canagliflozin 100 mg regardless of kidney function status; however, patients with moderately impaired kidney function experienced hyperkalemia more frequently with canagliflozin 300 mg compared with patients treated with either canagliflozin 100 mg or placebo. Canagliflozin was not associated with increased cardiovascular risk across studies; however, relatively few events among patients with impaired renal function meant that the analysis was not adequately powered to examine this outcome, and results from separate trials are awaited. Conclusions: Overall, canagliflozin is associated with small, transient changes in kidney function, and is well tolerated in patients with T2DM with varying kidney function status.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0300-7995
fulltext: fulltext
issn:
  • 0300-7995
  • 1473-4877
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5631979
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_infor
recordidTN_cdi_informaworld_taylorfrancis_310_1185_03007995_2015_1092128
sourceformatXML
sourcesystemPC
sourcerecordid1736681190
originalsourceidFETCH-LOGICAL-c357t-bf64fc4aede5abba617265782f2d39cd685e81cd30bff75830c837a72e811a843
addsrcrecordideNqFkE1LxDAURYMoOo7-BKVLNx3z0TSpbhTxCwRBdB1e00QiaTMmGWT89XaY0YULhcCDcO59j4PQEcEzQiQ_xQxj0TR8RjHhM4IbSqjcQhNSCVZWUohtNFkx5QraQ_spvWE8Ik2zi_ZoXTUVqdkEnT2ZAXxhrDU6pyLYQsMAr95ZHz7dUIwvL-emoEXnoDXZpKI33ru8SAdox4JP5nAzp-jl5vr56q58eLy9v7p8KDXjIpetrSurKzCd4dC2UBNBay4ktbRjje5qyY0kumO4tVZwybCWTICg4y8BWbEpOln3zmN4X5iUVe-SHo-AwYRFUkSwuh7ZBo8oX6M6hpSisWoeXQ9xqQhWK23qW5taaVMbbWPueLNi0fam-0l9exqB81_F2mXILgw5gvP_1l-s026wIfbwEaLvVIalD9FGGLRLiv1d8QXrFY12
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1736681190
display
typearticle
titleRenal effects of canagliflozin in type 2 diabetes mellitus
sourceAlma/SFX Local Collection
creatorPerkovic, Vlado ; Jardine, Meg ; Vijapurkar, Ujjwala ; Meininger, Gary
creatorcontribPerkovic, Vlado ; Jardine, Meg ; Vijapurkar, Ujjwala ; Meininger, Gary
descriptionBackground: Chronic kidney disease is commonly associated with type 2 diabetes mellitus (T2DM) and may impact the efficacy and safety of glucose-lowering therapies. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces blood glucose levels in patients with T2DM by lowering the renal threshold for glucose, thereby promoting urinary glucose excretion. This review describes the pharmacology, efficacy and safety of canagliflozin according to kidney function in participants with T2DM. Methods: Published articles that reported efficacy, safety and pharmacokinetics/pharmacodynamics data for canagliflozin in patients with T2DM and impaired renal function, and renal safety data with canagliflozin in various populations of patients with T2DM through May 2015 were included. Results: Early transient reductions in estimated glomerular filtration rate were observed with canagliflozin; these changes generally stabilized or attenuated over time and reversed after discontinuation, suggesting no renal (glomerular or tubular) damage with canagliflozin treatment. Urinary albumin-to-creatinine ratios were reduced with canagliflozin. Canagliflozin was generally well tolerated in patients with normal or mild to moderately impaired renal function, with a modestly higher incidence of renal-related adverse events and volume depletion-related adverse events in patients with moderate renal impairment. Adverse events related to potassium elevations were infrequent with canagliflozin 100 mg regardless of kidney function status; however, patients with moderately impaired kidney function experienced hyperkalemia more frequently with canagliflozin 300 mg compared with patients treated with either canagliflozin 100 mg or placebo. Canagliflozin was not associated with increased cardiovascular risk across studies; however, relatively few events among patients with impaired renal function meant that the analysis was not adequately powered to examine this outcome, and results from separate trials are awaited. Conclusions: Overall, canagliflozin is associated with small, transient changes in kidney function, and is well tolerated in patients with T2DM with varying kidney function status.
identifier
0ISSN: 0300-7995
1EISSN: 1473-4877
2DOI: 10.1185/03007995.2015.1092128
3PMID: 26494163
languageeng
publisherEngland: Taylor & Francis
subjectCanagliflozin ; Canagliflozin - adverse effects ; Canagliflozin - therapeutic use ; Chronic kidney disease ; Diabetes Mellitus, Type 2 - drug therapy ; Dose-Response Relationship, Drug ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Kidney ; Kidney - drug effects ; Kidney Function Tests ; Renal Insufficiency - physiopathology ; Renal Insufficiency, Chronic - physiopathology ; Safety ; Sodium-Glucose Transporter 2 - antagonists & inhibitors ; Type 2 diabetes mellitus
ispartofCurrent medical research and opinion, 2015-12-02, Vol.31 (12), p.2219-2231
rights2015 Taylor & Francis 2015
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-c357t-bf64fc4aede5abba617265782f2d39cd685e81cd30bff75830c837a72e811a843
citesFETCH-LOGICAL-c357t-bf64fc4aede5abba617265782f2d39cd685e81cd30bff75830c837a72e811a843
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26494163$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Perkovic, Vlado
1Jardine, Meg
2Vijapurkar, Ujjwala
3Meininger, Gary
title
0Renal effects of canagliflozin in type 2 diabetes mellitus
1Current medical research and opinion
addtitleCurr Med Res Opin
descriptionBackground: Chronic kidney disease is commonly associated with type 2 diabetes mellitus (T2DM) and may impact the efficacy and safety of glucose-lowering therapies. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces blood glucose levels in patients with T2DM by lowering the renal threshold for glucose, thereby promoting urinary glucose excretion. This review describes the pharmacology, efficacy and safety of canagliflozin according to kidney function in participants with T2DM. Methods: Published articles that reported efficacy, safety and pharmacokinetics/pharmacodynamics data for canagliflozin in patients with T2DM and impaired renal function, and renal safety data with canagliflozin in various populations of patients with T2DM through May 2015 were included. Results: Early transient reductions in estimated glomerular filtration rate were observed with canagliflozin; these changes generally stabilized or attenuated over time and reversed after discontinuation, suggesting no renal (glomerular or tubular) damage with canagliflozin treatment. Urinary albumin-to-creatinine ratios were reduced with canagliflozin. Canagliflozin was generally well tolerated in patients with normal or mild to moderately impaired renal function, with a modestly higher incidence of renal-related adverse events and volume depletion-related adverse events in patients with moderate renal impairment. Adverse events related to potassium elevations were infrequent with canagliflozin 100 mg regardless of kidney function status; however, patients with moderately impaired kidney function experienced hyperkalemia more frequently with canagliflozin 300 mg compared with patients treated with either canagliflozin 100 mg or placebo. Canagliflozin was not associated with increased cardiovascular risk across studies; however, relatively few events among patients with impaired renal function meant that the analysis was not adequately powered to examine this outcome, and results from separate trials are awaited. Conclusions: Overall, canagliflozin is associated with small, transient changes in kidney function, and is well tolerated in patients with T2DM with varying kidney function status.
subject
0Canagliflozin
1Canagliflozin - adverse effects
2Canagliflozin - therapeutic use
3Chronic kidney disease
4Diabetes Mellitus, Type 2 - drug therapy
5Dose-Response Relationship, Drug
6Humans
7Hypoglycemic Agents - adverse effects
8Hypoglycemic Agents - therapeutic use
9Kidney
10Kidney - drug effects
11Kidney Function Tests
12Renal Insufficiency - physiopathology
13Renal Insufficiency, Chronic - physiopathology
14Safety
15Sodium-Glucose Transporter 2 - antagonists & inhibitors
16Type 2 diabetes mellitus
issn
00300-7995
11473-4877
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqFkE1LxDAURYMoOo7-BKVLNx3z0TSpbhTxCwRBdB1e00QiaTMmGWT89XaY0YULhcCDcO59j4PQEcEzQiQ_xQxj0TR8RjHhM4IbSqjcQhNSCVZWUohtNFkx5QraQ_spvWE8Ik2zi_ZoXTUVqdkEnT2ZAXxhrDU6pyLYQsMAr95ZHz7dUIwvL-emoEXnoDXZpKI33ru8SAdox4JP5nAzp-jl5vr56q58eLy9v7p8KDXjIpetrSurKzCd4dC2UBNBay4ktbRjje5qyY0kumO4tVZwybCWTICg4y8BWbEpOln3zmN4X5iUVe-SHo-AwYRFUkSwuh7ZBo8oX6M6hpSisWoeXQ9xqQhWK23qW5taaVMbbWPueLNi0fam-0l9exqB81_F2mXILgw5gvP_1l-s026wIfbwEaLvVIalD9FGGLRLiv1d8QXrFY12
startdate20151202
enddate20151202
creator
0Perkovic, Vlado
1Jardine, Meg
2Vijapurkar, Ujjwala
3Meininger, Gary
generalTaylor & Francis
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
87X8
sort
creationdate20151202
titleRenal effects of canagliflozin in type 2 diabetes mellitus
authorPerkovic, Vlado ; Jardine, Meg ; Vijapurkar, Ujjwala ; Meininger, Gary
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c357t-bf64fc4aede5abba617265782f2d39cd685e81cd30bff75830c837a72e811a843
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Canagliflozin
1Canagliflozin - adverse effects
2Canagliflozin - therapeutic use
3Chronic kidney disease
4Diabetes Mellitus, Type 2 - drug therapy
5Dose-Response Relationship, Drug
6Humans
7Hypoglycemic Agents - adverse effects
8Hypoglycemic Agents - therapeutic use
9Kidney
10Kidney - drug effects
11Kidney Function Tests
12Renal Insufficiency - physiopathology
13Renal Insufficiency, Chronic - physiopathology
14Safety
15Sodium-Glucose Transporter 2 - antagonists & inhibitors
16Type 2 diabetes mellitus
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Perkovic, Vlado
1Jardine, Meg
2Vijapurkar, Ujjwala
3Meininger, Gary
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7MEDLINE - Academic
jtitleCurrent medical research and opinion
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Perkovic, Vlado
1Jardine, Meg
2Vijapurkar, Ujjwala
3Meininger, Gary
formatjournal
genrearticle
ristypeJOUR
atitleRenal effects of canagliflozin in type 2 diabetes mellitus
jtitleCurrent medical research and opinion
addtitleCurr Med Res Opin
date2015-12-02
risdate2015
volume31
issue12
spage2219
epage2231
pages2219-2231
issn0300-7995
eissn1473-4877
abstractBackground: Chronic kidney disease is commonly associated with type 2 diabetes mellitus (T2DM) and may impact the efficacy and safety of glucose-lowering therapies. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces blood glucose levels in patients with T2DM by lowering the renal threshold for glucose, thereby promoting urinary glucose excretion. This review describes the pharmacology, efficacy and safety of canagliflozin according to kidney function in participants with T2DM. Methods: Published articles that reported efficacy, safety and pharmacokinetics/pharmacodynamics data for canagliflozin in patients with T2DM and impaired renal function, and renal safety data with canagliflozin in various populations of patients with T2DM through May 2015 were included. Results: Early transient reductions in estimated glomerular filtration rate were observed with canagliflozin; these changes generally stabilized or attenuated over time and reversed after discontinuation, suggesting no renal (glomerular or tubular) damage with canagliflozin treatment. Urinary albumin-to-creatinine ratios were reduced with canagliflozin. Canagliflozin was generally well tolerated in patients with normal or mild to moderately impaired renal function, with a modestly higher incidence of renal-related adverse events and volume depletion-related adverse events in patients with moderate renal impairment. Adverse events related to potassium elevations were infrequent with canagliflozin 100 mg regardless of kidney function status; however, patients with moderately impaired kidney function experienced hyperkalemia more frequently with canagliflozin 300 mg compared with patients treated with either canagliflozin 100 mg or placebo. Canagliflozin was not associated with increased cardiovascular risk across studies; however, relatively few events among patients with impaired renal function meant that the analysis was not adequately powered to examine this outcome, and results from separate trials are awaited. Conclusions: Overall, canagliflozin is associated with small, transient changes in kidney function, and is well tolerated in patients with T2DM with varying kidney function status.
copEngland
pubTaylor & Francis
pmid26494163
doi10.1185/03007995.2015.1092128
oafree_for_read